We then validated the potency of BAX and BAK deficiency in the induction of drug resistance in DLD-1 WT and DLD-1 BAX–BAK DKO cells against FDA-approved drugs conventionally used for the therapies of cancer, inflammation and metabolic diseases, as tumorigenesis is closely related to inflammatory disorder and metabolic dysfunction (Coussens and Werb, 2002; Coller, 2014). Here, BAK1 is linked to metabolic disease.